We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 128.26 | 4 | 09:54:30 |
By Michael Dabaie
Merck & Co. Inc. said it is in a supply agreement with the Canadian government for up to 1 million patient courses of molnupiravir, its investigational oral antiviral medicine for the treatment of Covid-19.
Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics.
The government of Canada secured access in 2022 to 500,000 patient courses, with options for up to 500,000 more, pending Health Canada approval.
In November, Merck Canada filed the final wave of the molnupiravir rolling submission to Health Canada, which will decide on the therapy's approval when all necessary evidence has been reviewed.
The U.S. Food and Drug Administration's Antimicrobial Drugs Advisory Committee recently voted 13-10 that the known and potential benefits of molnupiravir outweigh its known and potential risks for the treatment of mild to moderate Covid-19 in high-risk adult patients. While the FDA isn't bound by the committee's guidance, it takes that advice into consideration.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 03, 2021 14:45 ET (19:45 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions